Biotinylated Human TRAIL R4/TNFRSF10D Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01250P-100UG

Biotinylated Human TRAIL R4 on Tris-Bis PAGE under reduced conditions. The purity is greater than 95%.
Biotinylated Human TRAIL R4/TNFRSF10D Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01250P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human TRAIL R4/TNFRSF10D Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Ala56-His211. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q9UBN6 |
Target Symbol | TRAIL R4/TNFRSF10D |
Synonyms | CD264; RSF10D; TRAILR4; DCR2; TRUNDD; TNFRSF10D |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Ala56-His211 |
Mol. Weight | The protein has a predicted MW of 19.4 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human TRAIL, No Tag at 5ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Human TRAIL R4, His Tag with the EC50 of 0.14ug/ml determined by ELISA (QC Test). The affinity constant of 0.135 nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. |